SCICLONE PHARMACEUTICALS INC (SCLN) Stock Price, Forecast & Analysis

NASDAQ:SCLN • US80862K1043

11.15
0 (0%)
At close: Oct 13, 2017
11.15
0 (0%)
After Hours: 10/13/2017, 8:10:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

SCLN Key Statistics, Chart & Performance

Key Statistics
Market Cap581.92M
Revenue(TTM)172.02M
Net Income(TTM)43.31M
Shares52.19M
FloatN/A
52 Week High11.43
52 Week Low8.55
Yearly Dividend0
Dividend Yield0%
EPS(TTM)0.82
PE13.64
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
SCLN short term performance overview.The bars show the price performance of SCLN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15

SCLN long term performance overview.The bars show the price performance of SCLN in the last 1, 2 and 3 years. 1 year 2 years 3 years 2 4 6 8 10

The current stock price of SCLN is 11.15 null. In the past month the price increased by 0.45%. In the past year, price increased by 11.39%.

SCICLONE PHARMACEUTICALS INC / SCLN Daily stock chart

SCLN Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to SCLN. When comparing the yearly performance of all stocks, SCLN turns out to be only a medium performer in the overall market: it outperformed 64.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
SCLN Full Technical Analysis Report

SCLN Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to SCLN. SCLN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SCLN Full Fundamental Analysis Report

SCLN Financial Highlights

Over the last trailing twelve months SCLN reported a non-GAAP Earnings per Share(EPS) of 0.8174. The EPS increased by 9.69% compared to the year before.


Industry RankSector Rank
PM (TTM) 25.18%
ROA 15.6%
ROE 17.34%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%90.75%
Sales Q2Q%14.18%
EPS 1Y (TTM)9.69%
Revenue 1Y (TTM)6.69%
SCLN financials

SCLN Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y-100%
Revenue Next YearN/A
SCLN Analyst EstimatesSCLN Analyst Ratings

SCLN Ownership

Ownership
Inst Owners72.8%
Ins Owners1.35%
Short Float %N/A
Short RatioN/A
SCLN Ownership

About SCLN

Company Profile

Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.

Company Info

SCICLONE PHARMACEUTICALS INC

950 TOWER LANE SUITE 900

FOSTER CITY CA 94404

CEO: Friedhelm Blobel

Phone: 650-358-3456

SCICLONE PHARMACEUTICALS INC / SCLN FAQ

What does SCICLONE PHARMACEUTICALS INC do?

Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.


Can you provide the latest stock price for SCICLONE PHARMACEUTICALS INC?

The current stock price of SCLN is 11.15 null.


Does SCLN stock pay dividends?

SCLN does not pay a dividend.


What is the ChartMill rating of SCICLONE PHARMACEUTICALS INC stock?

SCLN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Is SCICLONE PHARMACEUTICALS INC (SCLN) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCLN.


Can you provide the ownership details for SCLN stock?

You can find the ownership structure of SCICLONE PHARMACEUTICALS INC (SCLN) on the Ownership tab.